[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psychotic-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psychotic-disorder":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,52,88,114,143,175,197,223,246,271],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100613164","phase-3-cognitive-strategies-in-early-psychosis-2-100613164",false,"NCT07263022","Cognitive Strategies in Early Psychosis 2","COSTEP 2","Inclusion Criteria:\n\n* Between the ages of 18 and 35\n* Onset of a psychosis spectrum illness (schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis NOS, bipolar disorder with psychosis, or major depressive disorder with psychosis) within 5 years of enrollment\n* Estimated IQ of 70 or above\n* Proficient at English as determined through interactions with the study team\n* No change in psychiatric medication within a week of enrollment or MRI study visits\n* No clinically significant change in any medications for at least 1 month prior to study participation or MRI study visits, as determined by PI\u002FCo-Is\n\n  * Participants may have minor adjustments in medication doses in the past 30 days, per PI discretion, but may not have had major increases or decreases in doses, or additions or removal of medication within the past 30 days.\n  * Participants are to have no changes to medications in the past 7 days before drug administration (i.e., must have been on a stable dose for at least 7 days prior to receiving the study drug).\n\nExclusion Criteria:\n\nMedical Criteria:\n\n* Presence of the following medical concerns as determined by the study PI:\n\n  * Major neurological disorder\n  * History of a clinically significant head injury with or without prolonged unconsciousness\n  * Any major medical condition that, in the opinion of the PI, would impede participation in the study or would put the participant at additional risk by participating\n* History of any of the following as reported by the participant:\n\n  * Renal impairment, injury, or disease\n  * Hepatic impairment, injury, or disease\n  * Myocardial infarction or heart disease, or endorsement of history of or of cardiac symptoms at intake:\n\n    * Dyspnea\n    * Palpitations\n    * Orthopnea\n    * Pedal oedema\n    * Significant dizziness\n    * Syncope\n    * Claudication\n  * Low white blood cell count, or is diagnosed with leukopenia, neutropenia, or agranulocytosis\n* Presence of unmanaged hypertension (\\>140\u002F90) or elevated resting heart rate (\\>100 bpm)\n* Abnormal clinical laboratory values:\n\n  * uACR \\> 30 mg\u002Fg\n  * creatinine level \\>0.95 mg\u002FdL\n  * AST or ALT \\> 50 U\u002FL\n  * Bilirubin \\> 1.2 mg\u002FdL\n  * Total Protein \\\u003C 6 g\u002FdL\n* Taking a medication or supplement that has a major drug interaction with any study drugs (e.g., ketamine, MAOIs, clomipramine, diazepam, propranolol, warfarin)\n* Allergies to study drugs\n* Is pregnant, planning to become pregnant, or is breastfeeding\n* Cannot pass the visual acuity test\n* Cannot pass the CMRR Subject Safety Screen due to MRI contraindications\n\nMental health criteria:\n\n* Meets criteria for a severe substance or alcohol use disorder within 3 months of enrollment\n* Lifetime history of a stimulant use disorder\n* Current manic episode as determined by the MINI\n* History of psychiatric hospitalization within 3 months of enrollment\n* Meets criteria for clinical risk of suicidal behavior, as defined by:\n\n  * Clinician judgment\n  * A suicide attempt within 3 months of enrollment\n  * Active suicidal ideation at screening or baseline, as indicated by the C-SSRS Screener\n  * Previous intent to act on suicidal ideation with a specific plan and\u002For preparatory acts within 3 months of enrollment, as indicated by the C-SSRS Screener\n* Symptom severity scores in the severe (6) or extremely severe (7) range on the BPRS for the following items: suicidality, disorientation, bizarre behavior, excitement, elevated mood\n* Any other psychiatric symptoms or conditions that, in the opinion of the PI, would impede participation in the study or put the participant at additional risk by participating\n\nOther criteria:\n\n* Unable or unwilling to provide informed consent\n* Unable to demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in the research study\n* Current guardianship\n* Is under civil commitment or under a stay of civil commitment\n* Illiteracy\n* Has engaged in significant cognitive training, in the opinion of the PI, in the last year","ALL","18 Years","35 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last five years. The investigators will study how two study agents change decision making in people with psychosis, by asking participants to complete some brain games on the computer before and after taking the study agents. The investigators hope to improve our understanding of psychosis to help people in the future. The main research questions are:\n\n* Does a single dose of modafinil change how people with psychosis play the brain games?\n* Does a single dose of d-serine change how people with psychosis play the brain games?\n* Does a single dose of modafinil change brain activity?\n* Does a single dose of d-serine change brain activity?\n\nParticipants will:\n\n* Complete an interview and self-report questionnaires.\n* Complete safety screening activities, like a blood draw, a urine drug test, and an alcohol breathalyzer test.\n* Complete functional Magnetic Resonance Imaging (fMRI) scans. fMRI uses magnets to take pictures of the brain. There will be six scanning appointments in the study, with two scans each. Appointments will be about a month apart.\n* Take a single dose of a study agent during each scanning appointment. The study agent will be taken after the first fMRI. There are three study agents in total: modafinil, d-serine, and a placebo. Each participant will take each study agent twice during the study.\n* Play brain games on a computer that measure decision making, thinking, and problem solving skills",[27,28,29,30,31,32,33,34,35],"Psychosis","Schizophrenia Disorder","Schizoaffective Disorder","Major Depressive Disorder With Psychotic Features","Bipolar Disorder With Psychotic Features","Psychosis NOS","Schizophreniform Disorder","Psychotic Disorder","Cognition",[35,37,38,39],"Decision Making","fMRI","Psychosis spectrum disorders","NOT_YET_RECRUITING","2026-05-28",{"date":43,"type":44},"2026-05-29","ACTUAL",{"date":46,"type":21},"2026-07-07",{"date":48,"type":21},"2030-04-30",{"name":50,"class":51},"University of Minnesota","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100435059","study-of-self-recognition-and-selfother-distinction-disorders-in-patients-with-psychological-vulnerability-100435059","NCT04945278","Study of Self-Recognition and Self\u002FOther Distinction Disorders in Patients With Psychological Vulnerability","Study of Self-Recognition and Self\u002FOther Distinction Disorders in Patients With Psychological Vulnerability (ALTER EGO)","ALTER-EGO","Inclusion criteria for patients:\n\n* Aged from 15 to 25 years\n* Subject meeting the Ultra High Risk criteria at CAARMS and \u002F or SPI-A\n* Signature of the consent (participants and parents for minors)\n* Subject affiliated to the social security scheme or benefiting from such a scheme\n\nInclusion criteria for healthy volunteers:\n\n* Aged from 15 to 25 years\n* Subject not familiar to the patient to whom it is matched\n* Signature of the consent (participants and parents for minors)\n* Subject affiliated to the social security scheme or benefiting from such a scheme\n\nExclusion Criteria for both patients and healthy volunteers:\n\n* History of epilepsy and \u002F or migraine (due to the epileptogenic potential of light stimuli)\n* Refusal of participation of the minor even if the legal representatives want the subject to participate in the study\n* Claustrophobia\n* Wearing glasses\n* Abnormal right and left visual acuity without contact lenses\n* Distinctive signs on the face which cannot be temporarily removed\n* Subject under legal protection (curators \u002F guardianship) or deprived of liberty",true,"15 Years","25 Years",{"count":64,"type":21},34,[66],"NA","The main objective of this study is to establish whether there are differences in self-recognition and self\u002Fother distinction in subjects with psychological vulnerability compared to healthy volunteer controls.",[69,34],"Psychosis of Childhood Borderline",[71,72,73,74,75,76],"Mental Vulnerability","Self-recognition","Psychosis High-Risk State","Self-other Distinction","Double Mirror Paradigm","Schizophrenia","RECRUITING","2026-03-18",{"date":80,"type":44},"2026-03-19",{"date":82,"type":44},"2022-05-31",{"date":84,"type":21},"2027-07-31",{"name":86,"class":51},"University Hospital, Brest",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100582952","psychotropic-drug-induced-qt-prolongation-and-ecg-monitoring-in-the-pediatric-population-100582952","NCT06870006","Psychotropic-Drug-induced QT Prolongation and ECG Monitoring in the Pediatric Population","Inclusion Criteria:\n\n* Admitted to psychiatry ward\n* Starting a psychotropic drug acting on QT interval\n\nExclusion Criteria:\n\n* Age \\>18aa\n* History of administration of drug acting on QT interval in the 3 months prior",{"count":95,"type":21},100,"OBSERVATIONAL","Electrocardiogram (ECG) Q-T prolongation is a cardiac electrophysiological disorder associated with the occurrence of arrhythmias potentially fatal. Several psychotropic drugs are associated with an increased risk of QT prolongation, which is why in clinical practice a baseline ECG is performed before a psychotropic drug is prescribed. However, there are no validated protocols establishing when to repeat this examination or describing clinical events when this examination should be repeated in clinical follow-up.\n\nThe study aims to investigate the incidence of QTc prolongation events as a side effect of chronic psychotropic drug administration. For this purpose, ECGs will be recorded and confounding factors of patients at the beginning of psychotropic therapy and after 3, 6 and 12 months will be analyzed.",[99,100,34,101],"Eating Disorders","Mood Disorders in Children and Adolescents","QTc Intervals Changes",[103,104],"QTc interval","psychotropic drugs","2026-03-17",{"date":78,"type":44},{"date":108,"type":44},"2024-01-01",{"date":110,"type":21},"2027-01",{"name":112,"class":51},"Meyer Children's Hospital IRCCS",6,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":60,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":87},"100593759","brain-stimulation-to-the-hippocampus-in-schizophrenia-100593759","NCT07010614","Brain Stimulation to the Hippocampus in Schizophrenia","Theta Burst Modulation of Hippocampal-Cortical Rhythms in Schizophrenia","Inclusion Criteria:\n\n* Men and women, ages 18 to 65 years\n* Medically intractable epilepsy requiring phase II monitoring (intracranial EEG arms only)\n* DSM-V diagnosis of schizophrenia spectrum Axis I disorders including delusional disorder, brief psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder (non-invasive TMS-EEG arms only).\n* Must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent\n* No current or history of major neurological disorders other than epilepsy.\n\nExclusion Criteria:\n\n* DSM5 diagnosis of intellectual disability\n* Significant head injury\n* Active suicidal ideation or history of suicide attempt within the past 1 year.\n* Medical illness affecting brain structure or function, or other uncontrolled or unstable medical condition.\n* Pregnancy or postpartum (\\\u003C6 weeks after delivery or miscarriage)\n* Inability to provide informed consent\n* Active substance abuse other than alcohol or cannabis within the past 1 year\n* Psychotic illness with a temporal relation to substance use or head injury\n* Those with a contraindication for MRIs or TMS (e.g. implanted metal).","65 Years",{"count":123,"type":21},60,[66],"Schizophrenia - marked by delusions, hallucinations, and cognitive deficits - causes the most disability of any mental health condition, but existing treatments have significant side effect burden and are often ineffective. Disordered neural activity in the hippocampus likely contributes to schizophrenia symptoms, but to develop better therapies we need to understand whether hippocampal activity in schizophrenia can be systematically affected by non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS). This proposal will investigate the use of connectivity-guided theta burst brain stimulation to specifically target hippocampal function in schizophrenia, offering insights into fundamental hippocampal processes, schizophrenia pathophysiology, and potential avenues to use brain stimulation as a therapeutic tool in this devastating illness.",[127,128,34],"Schizophrenia Disorders","Mental Disorder",[130,131,132,133],"schizophrenia","transcranial magnetic stimulation","TMS","EEG","2026-02-25",{"date":136,"type":44},"2026-02-27",{"date":138,"type":44},"2025-10-01",{"date":140,"type":21},"2027-09-30",{"name":142,"class":51},"Stanford University",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":87},"100620556","changing-lives-and-changing-outcomes-9-at-worcester-recovery-center-and-hospital-100620556","NCT07359157","Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital","Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital: Implementing and Evaluating A Mental Illness and Criminal Risk Focused Intervention for People With Serious Mental Illness","CLCO-9","Inclusion Criteria:\n\n* Currently hospitalized at Worcester Recovery Center and Hospital (WRCH)\n* At least 18 years old\n* Self-reported current or past legal involvement\n* Speaks English\n* For patients without a legally authorized representative (LAR): demonstrate capacity to consent per the Capacity Assessment Record (CAR).\n* For patients with an LAR: assent to participate.\n\nExclusion Criteria:\n\n* Hospital status that does not permit group attendance (e.g., room-based seclusion)",{"count":152,"type":21},40,[66],"People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement.\n\nThe investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims:\n\n1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH\n2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement\n3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement.\n\nTo test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment.\n\nAll patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.",[156,34,157,158],"Serious Mental Illness","Depression","Bipolar",[160,161,162,163,164,165],"serious mental illness","criminogenic risk","criminal legal involvement","treatment","forensic","state hospital","2026-02-12",{"date":168,"type":44},"2026-02-17",{"date":170,"type":44},"2026-02-05",{"date":172,"type":21},"2026-07-01",{"name":174,"class":51},"Massachusetts General Hospital",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":60,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":183,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100623541","speech-based-assessment-of-relapse-risk-in-people-with-psychosis-100623541","NCT07397975","Speech-based Assessment of Relapse Risk in People With Psychosis","A Prospective Multicenter Study for Relapse Risk Assessment Through Language Analysis in Individuals With Psychosis","TRUSTING-WP4","Healthy participants Inclusion Criteria:\n\n* Between 18 and 65 years old.\n* Subjects must be able to provide informed consent (IC).\n* Participants must have provided signed informed consent prior to enrollment.\n* Participants should not take prescription drugs regularly.\n* Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish.\n* Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection.\n* Must be able to comply with the study schedule and procedures.\n\nHealthy participants Exclusion Criteria:\n\n* Any history of major diseases (e.g., cardiovascular, neurological, metabolic, renal, hepatic, respiratory or speech disorders).\n* Recreational drug use or psychiatric disorders due to use of alcohol.\n* Depression, anxiety, or other psychiatric disorders.\n* Family history of depression, anxiety, or other psychiatric disorders.\n* Individuals who are not able or willing to understand the purpose and details of the study.\n\nIndividuals with psychosis Inclusion Criteria:\n\n* Between 18 and 65 years old.\n* Diagnoses include psychotic disorders (schizophrenia, schizoaffective disorder, schizophreniform disorder, acute psychosis, bipolar disorder with psychotic symptoms, psychosis not otherwise specified).\n* First visit must be during remission phase (baseline measurement).\n* Current positive symptoms rated 3 (mild) or lower on all of these Brief Psychiatric Symptom Scale (BPRS) items: hallucinatory behavior, unusual thought content, conceptual disorganization.\n* Must be able to comply with the study schedule and procedures.\n* Subjects must be able to provide IC.\n* Participants must have provided signed informed consent prior to enrollment.\n* Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish.\n* Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection.\n\nIndividuals with psychosis Exclusion Criteria:\n\n* Severe comorbid speech disorders (aphasia or severe stuttering) that prevent adequate speech recording.\n* Individuals who are not able or willing to understand the purpose and details of the investigation.\n\nCitizens with psychiatric or somatic comorbidity, drug- or alcohol abuse will be allowed to participate, so that the sample will reflect the general population of citizens with psychosis and the study's endpoints will be generalizable.",{"count":184,"type":21},360,"This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.",[34],"2026-02-02",{"date":189,"type":44},"2026-02-09",{"date":191,"type":44},"2026-01-29",{"date":193,"type":21},"2029-01-31",{"name":195,"class":51},"Philipp Homan",7,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100600490","randomized-clinical-trial-of-itest-a-blended-intervention-targeting-introspective-accuracy-100600490","NCT07098169","Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy","iTEST R33","Inclusion Criteria:\n\n1. Voluntary informed consent to participate and capacity to consent as measured by the UCSD Brief Assessment of Capacity to Consent (UBACC)\n2. Age 18 to 65;\n3. DSM-5 diagnosis of schizophrenia or schizoaffective disorder based on a structured diagnostic interview and available medical record review;\n4. ≥ 6th grade reading level on the Wide Range Achievement Test-4 Reading subtest (needed to read instructions on device);\n5. Stable co-treatments (no hospitalizations or medication class changes in 2 months before enrollment). The investigators will determine symptom and medication stability by best-estimate history with information from medical records;\n6. Availability of a clinician (staff member, case manager, other mental health clinician) or close associate (family member, friend) with at least monthly contact who can be their informant\n7. Minimum level of functional impairment based on milestones, excluding participants who are full-time employed and financially responsible for their household.\n\nExclusion Criteria:\n\n1. Greater than moderate disorganization on the Positive and Negative Syndrome Scale (P2-Disorganization item \\>5)\n2. DSM-5 alcohol or substance dependence in past 3 months based on interview\n3. Level of care required interferes with outpatient therapy (e.g., hospitalized; severe medical illness); 4) Unable to adequately see or manually manipulate a smartphone.",{"count":205,"type":21},201,[66],"The purpose of this study is to evaluate the effectiveness of a psychosocial intervention called iTEST for people with psychotic disorders that targets introspective accuracy, or the ability to accurately gauge ones abilities. iTEST combines daily cognitive training on a mobile device with coaching that addresses recovery goals. In this trial, we will randomize people to one of two interventions conditions, iTEST or a control condition that receives coaching and cognitive training that does not emphasize introspective accuracy. Both interventions will take place over 12 weeks and participants will be asked to complete assessments at baseline, 6 weeks, 12 weeks, and 24 weeks. The primary outcome of the study is community functioning. Participants will be from three metropolitan areas: San Diego, Dallas, or Miami.",[127,29,34],[210,211,76,27,212],"Digital health","Cognitive training","Functional rehabilitation","2026-01-22",{"date":215,"type":44},"2026-01-23",{"date":217,"type":44},"2025-09-01",{"date":219,"type":21},"2028-04-01",{"name":221,"class":51},"University of California, San Diego",3,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":87},"100619328","deprescribing-antipsychotics-a-multiple-case-study-100619328","NCT07343193","Deprescribing Antipsychotics: a Multiple Case Study","DEPRESC","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Patients with a psychotic or related disorder\n* Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025\n\nExclusion Criteria:\n\n\\- Patients who have expressed their opposition to participating in the study",{"count":231,"type":21},30,"The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc.\n\nThe fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments.\n\nThis argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.",[34],[34,235,236],"Psychotic or Related Disorder","Antipsychotics","2026-01-06",{"date":239,"type":44},"2026-01-15",{"date":241,"type":44},"2025-09-09",{"date":243,"type":21},"2026-09-09",{"name":245,"class":51},"University Hospital, Strasbourg, France",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":87},"100601640","effects-of-a-long-term-exercise-training-program-on-the-functional-capacity-and-health-related-quality-of-life-in-inpatients-with-psychotic-disorders-100601640","NCT07113119","Effects of a Long-term Exercise Training Program on the Functional Capacity and Health-related Quality of Life in Inpatients With Psychotic Disorders","Inclusion Criteria:\n\n* being an adult\n* inpatient with a diagnosis of psychotic syndrome\n* on stable medication\n* controlled as far as psychosis is concerned\n* consenting to participate\n\nExclusion Criteria:\n\n* adolescents\n* with other diagnoses\n* not on stable medication\n* in an unstable condition\n* unwilling to participate in the study",{"count":253,"type":21},48,[66],"Mental health represents a fundamental dimension of overall well-being, exerting a significant influence on mortality rates, health-related quality of life (HRQoL), levels of disability, and the strain on healthcare systems. As the interest in mental wellness continues to grow, exercise training (ET) has become increasingly recognized as a validated and effective intervention for individuals experiencing mental health challenges. An expanding body of research underscores the adverse effects of physical inactivity, reinforcing the role of exercise as a viable therapeutic strategy.\n\nWell-structured ET interventions have consistently demonstrated benefits across multiple domains, including improvements in physical health, reductions in cardiovascular risk, and enhancements in psychological constructs such as depression, self-esteem, resilience, and self-efficacy. However, the majority of prior studies have been limited to relatively short durations-typically ranging from 4 to 24 weeks, with an average of about 12 weeks. A significant gap in the literature persists regarding the long-term implementation and effectiveness of ET programs, particularly in populations with severe mental illness. Additionally, the small sample sizes commonly seen in previous studies restrict the statistical robustness and generalizability of their outcomes.\n\nThe aim of the randomized control trial is to examine whether an 1-year mixed type exercise training program within the hospital setting will improve functional capacity and health-related quality of life. Forty- eight participants will be randomly allocated into two groups: Group A (Exercise group) will receive 3 exercise sessions per week for 1-year and Group B (Control Group) will continue their usual care, without participating in organized exercise programs. Prior to the group random allocation, part of the assessment at the baseline and 1 year follow-up will include lower extremity strength test, muscle power using a dynamometer, aerobic capacity test, balance test, body positioning and health- related quality of life.",[34],[258,259,260,261],"Exercise","Functional ability","Quality of life","Pilates","2025-08-06",{"date":264,"type":44},"2025-08-08",{"date":266,"type":44},"2024-08-04",{"date":268,"type":21},"2025-08-15",{"name":270,"class":51},"Aristotle University Of Thessaloniki",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100473135","tdcs-for-cognitive-impairment-associated-with-recent-onset-schizophrenia-100473135","NCT05440955","tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia","Efficacy and Auditory Biomarker Analysis of Fronto-Temporal Transcranial Direct Current Stimulation (tDCS) in Targeting Cognitive Impairment Associated With Recent-onset Schizophrenia: A Randomized Double-blind Sham-controlled Trial","STICOG","The inclusion criteria include:\n\n1. subjects of both genders, diagnosed with recent-onset schizophrenia (first 3 years of illness), confirmed through the Structured Clinical Interview for the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition (SCID-5);\n2. aged 18-35 years;\n3. intelligence quotient (IQ) \\> 55;\n4. cognitive deficit confirmed by a MCCB (MATRICS Cognitive Consensus Battery) total score T-score \\\u003C 40;\n5. the subjects should be receiving stable doses of antipsychotics for ≥ 4 weeks;\n6. the subjects are covered by a public health insurance.\n\nThe exclusion criteria include:\n\n1. pregnant (controlled by urine pregnancy test in females of childbearing age) or breastfeeding women;\n2. unstable or acute medical conditions;\n3. subjects who receive involuntary treatment or guardianship;\n4. history of cranioencephalic trauma with loss of consciousness or central nervous system diseases that affect the brain;\n5. use of drugs that affect cognitive performance such as anticholinergic agents and benzodiazepines;\n6. current diagnosis of substance abuse or history of substance dependence in the last 6 months, except nicotine;\n7. MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) or tDCS (transcranial Direct Current Stimulation) contraindications",{"count":123,"type":21},[66],"Background: In parallel to the traditional symptomatology, deficits in cognition (memory, attention, reasoning, social functioning) contribute significantly to disability and suffering in individuals with schizophrenia. Cognitive deficits have been closely linked to alterations in early auditory processes (EAP) that occur in auditory cortical areas. Preliminary evidence indicates that cognitive deficits in schizophrenia can be improved with a reliable and safe non-invasive brain stimulation technique called tDCS (transcranial Direct Current Stimulation). However, a significant proportion of patients derive no cognitive benefits after tDCS treatment. Further, the neurobiological mechanisms of cognitive changes after tDCS have been poorly explored in trials and are thus still unclear.\n\nMethod: The study is designed as a randomized, double-blind, 2-arm parallel-group, sham controlled, 4-centers trial. Sixty participants with recent-onset schizophrenia and cognitive impairment will be randomly allocated to receive either active (n=30) or sham (n=30) tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays). The anode will be placed over the left dorsolateral prefrontal cortex and the cathode over the left auditory cortex. Cognition, tolerance, symptoms, general outcome and EAP (measured with EEG and multimodal MRI) will be assessed prior to tDCS (baseline), after the 10 sessions, and at 1- and 3-month follow-up. The primary outcome will be the number of responders, defined as participants demonstrating a cognitive improvement ≥Z=0.5 from baseline on the MATRICS Consensus Cognitive Battery total score at 1-month follow-up. Additionally, we will measure how differences in EAP modulate individual cognitive benefits from active tDCS and whether there are changes in EAP measures in responders after active tDCS.\n\nDiscussion: Besides proposing a new fronto-temporal tDCS protocol by targeting the auditory cortical areas, we aim to conduct an RCT with follow-up assessments up to 3-months and a large sample size. In addition, this study will allow identifying and assessing the value of a wide range of neurobiological EAP measures for predicting and explaining cognitive deficits improvement after tDCS. The results of this trial will constitute a step toward the use of tDCS as a therapeutic tool for the treatment of cognitive impairment in recent-onset schizophrenia.",[76,34],[130,284,285,286,287],"cognitive impairment","tDCS","early auditory processing","clinical trial","2023-04-03",{"date":290,"type":44},"2023-04-04",{"date":292,"type":21},"2023-06-01",{"date":294,"type":21},"2027-06-01",{"name":296,"class":51},"University Hospital, Grenoble",4]